Top Back to top

Current Management to Prevent and Treat CD19+ and BCMA+ CAR-T Cell Therapy-Related Complications

Transplant Complications Working Party (TCWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Complications: non-infectious
Short title:
CAR-T Complications Survey
Primary objective:
Key inclusion criteria:
All EBMT member countries
Principal investigator:
Olaf Penack
EBMT Study coordinator:
William Boreland
Study coordinator email:
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Not processing patients' personal data
Categories of personal data collected:
Not processing patients' personal data
Recipients who may access the data:
Paris Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 15 years after completion or discontinuation of the study (WP/NIS)